Kembali ke Daftar Obat

Panduan penyiapan dan pemberian terapi medikasi
Ampicillin Sodium

Penyiapan

Sediaan

  • 125 mg
  • 250 mg
  • 500 mg
  • 1 g
  • 2 g

Rekomendasi Pengenceran (Konsentrasi)

56mg/cc (500mg dalam 10ml, 1gr dalam 20cc, 2gr dalam 40cc)

Pelarut

  • NaCl 0.9%

Pemberian

Rekomendasi Akses

IV
IM

Rekomendasi Durasi Pemberian

Stabilitas Obat Setelah Rekonstruksi

24 jam dalam 27C

Keamanan

pH

8-10
pH risiko sedang (4,0-5,0 / 7,5-9,0)

Osmolaritas Sesudah Pengenceran

100mg/ml dalam ns 0,9%= 664
56mg/ml dalam NS0,9% = 576
10mg/ml dalam NS 0,9% =328
20mg/ml dalam NS 0,9% = 368-372
Osmolaritas rendah (<600)

Phlebitis

Tidak

Inkompatibilitas

  • D5%
  • Amikacin Sulfate
  • Aztreonam
  • Cefepime HCl
  • Chlorpromazine HCl
  • Dextrose 40%
  • Fat Emulsion
  • Gentamicin Sulfate
  • Heparin Sodium
  • Hetastratch
  • Hydralazine HCl
  • Hydrocortisone Sodium Succinate
  • Prochlorperazine Mesylate
  • Sodium Bicarbonate
  • Hydromorphone HCl
  • Lidocaine HCl
  • Metoclopramide HCl
  • Polymyxin B Sulfate
  • Streptomycin Sulfate
  • Calcium Gluconate
  • Caspofungin Acetate
  • Cisatracurium Besylate
  • Diltiazem HCl
  • Epinephrine HCl
  • Fenoldopam Mesylate
  • Fluconazole
  • Midazolam HCl
  • Nicardipine HCl
  • Ondansetron HCl
  • Sargramostim
  • Verapamil HCl
  • Vinorelbine Tartrate

Klasifikasi GHS

Irritant
Health Hazard

Manifestasi GHS

H317 (99.1%): May cause an allergic skin reaction [Warning Sensitization, Skin]
H334 (99.4%): May cause allergy or asthma symptoms or breathing difficulties if inhaled [Danger Sensitization, respiratory]

Sumber

  • American Society of Health-System Pharmacists. 2021. ASHP® Injectable Drug Information: A Comprehensive Guide to Compatibility and Stability. 2021 Edition. eBook. American Society of Health-System Pharmacists. ISBN: 978-1-58528-690-4. doi.org/10.37573/9781585286850
  • Manrique-Rodríguez, S., Heras-Hidalgo, I., Pernia-López, M.S. et al. Standardization and Chemical Characterization of Intravenous Therapy in Adult Patients: A Step Further in Medication Safety. Drugs R D 21, 39–64 (2021). https://doi.org/10.1007/s40268-020-00329-w